Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine

J. Remon, F. Tabbò, B. Jimenez, A. Collazo, J. de Castro, S. Novello

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)

Abstract

Next-generation ALK TKIs have become the new standard of care in first-line setting in advanced ALK-positive NSCLC patients. However, sequential strategies at progression are relevant, as may have an impact on patients’ outcome. In this commentary we discuss whether genomic-tailored strategies at progression would be more suitable for improving outcome of ALK-positive NSCLC patients.

Original languageEnglish
Pages (from-to)1425-1429
Number of pages5
JournalClinical and Translational Oncology
Volume22
Issue number9
DOIs
Publication statusPublished - 1 Sept 2020
Externally publishedYes

Keywords

  • ALK
  • Liquid biopsy
  • Next-generation
  • Non-small cell lung cancer
  • Sequential treatment

Cite this